C Féray, L Caccamo, GJM Alexander, B Ducot, J … - Gastroenterology, 1999 - Elsevier In 1994 a questionnaire was sent to 56 liver transplant centers, all members of the European
Liver Transplantation Registry, asking for data on all anti-HCV–positive patients (by second-generation
test) who had undergone liver transplantation. The first part of the questionnaire included ... Cited by 271 - Related articles - All 5 versions
- ►nih.gov [PDF] M Berenguer, FX López-Labrador, TL Wright - Journal of hepatology, 2001 - Elsevier Hepatitis C virus (HCV) infection is a prevalent infection in most developed countries affecting
1.5–2% of the general population [1]. The natural history of this infection has been extensively
evaluated. One of the most striking features is the high risk of persistence after viral ... Cited by 227 - Related articles - BL Direct - All 16 versions
- ►angrylapdog.com MA Keller, ER Stiehm - Clinical microbiology reviews, 2000 - Am Soc Microbiol Antibodies have been used for over a century in the prevention and treatment of infectious
disease. They are used most commonly for the prevention of measles, hepatitis A, hepatitis
B, tetanus, varicella, rabies, and vaccinia. Although their use in the treatment of bacterial ... Cited by 119 - Related articles - BL Direct - All 10 versions
- ►nih.gov D Lavillette, Y Morice, G Germanidis, P Donot, A … - Journal of …, 2005 - Am Soc Microbiol The factors leading to spontaneous clearance of hepatitis C virus (HCV) or to viral persistence
are elusive. Understanding virus-host interactions that enable acute HCV clearance is key to
the development of more effective therapeutic and prophylactic strategies. Here, using a ... Cited by 100 - Related articles - All 11 versions
- ►nih.gov KG Hadlock, RE Lanford, S Perkins, J Rowe, Q … - Journal of …, 2000 - Am Soc Microbiol The intrinsic variability of hepatitis C virus (HCV) envelope proteins E1 and E2 complicates the
identification of protective antibodies. In an attempt to identify antibodies to E2 proteins from divergent
HCV isolates, we produced HCV E2 recombinant proteins from individuals infected with ... Cited by 86 - Related articles - BL Direct - All 6 versions
- ►nih.gov [PDF] NA Terrault - Clinics in Liver Disease, 1999 - Elsevier Hepatitis B virus (HBV) infection affects more than 300 million persons worldwide and is ranked
among the top 10 lethal infectious diseases by the World Health Organization. 45 Liver transplantation
is the treatment of choice for patients with liver failure caused by acute or chronic HBV- ... Cited by 85 - Related articles - BL Direct - All 8 versions
JE Everhart, Y Wei, H Eng, MR Charlton, DH … - Hepatology, 1999 - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ... Cited by 85 - Related articles - BL Direct - All 4 versions
- ►pnas.org MW Yu, B Bartosch, P Zhang, Z Guo, PM … - Proceedings of the …, 2004 - National Acad Sciences The role of humoral immunity in hepatitis C virus (HCV) infections is uncertain. Nevertheless,
there is increasing evidence for neutralizing antibodies to HCV in the serum or plasma of chronically
infected individuals. Immune globulins prepared by ethanol fractionation of plasma had ... Cited by 81 - Related articles - BL Direct - All 11 versions
- ►pasteur.ac.ir [PDF] KQ Hu, JM Vierling, AG Redeker - Journal of viral hepatitis, 2001 - ingentaconnect.com Page 1. REVIEW Viral, host and interferon-related factors modulating the effect of interferon
therapy for hepatitis C virus infection Ke-Qin Hu, 1 John M. Vierling 2 and Allan G. Redeker
3 1 Department of Medicine and Transplantation Institute, Loma ... Cited by 69 - Related articles - BL Direct - All 4 versions
- ►nih.gov JM Heile, YL Fong, D Rosa, K Berger, G Saletti, S … - Journal of …, 2000 - Am Soc Microbiol Hepatitis C virus (HCV) is the leading causative agent of blood-borne chronic hepatitis and is
the target of intensive vaccine research. The virus genome encodes a number of structural and
nonstructural antigens which could be used in a subunit vaccine. The HCV envelope ... Cited by 66 - Related articles - BL Direct - All 9 versions
